1. Dexcom CGM System– Measuring blood glucose levels 24 hours a day, compatible with Apple Watch and Fitbit
This FDA approved CGM system is capable of determining levels of blood glucose in diabetic kids age two and above as well as adults.
The Dexcom CGM system comprises of the following components:
A tiny sensor for glucose levels measurement just beneath the skin.
A transmitter that fixes on top of the sensor and performs wireless sending of glucose data to your display device
A supporting smart device or little receiver displaying real-time information regarding glucose.
Over and above that, the CGM system offers customizable alerts for warning the user of approaching the rise and falls of glucose.
Dexcom CGM System can be integrated with other supporting electronic interfaces as well as medical devices. This is what sets it apart from its competitors. In this regard, other supporting devices can possibly be insulin pumps, automated systems of insulin dosing as well as blood glucose meters. In addition, it also includes some other electronic devices intended to manage diabetes.
Here is a short video demonstration on how to replace the sensor of the latest generation of Dexcom’s CGM device – the Dexcom G6
Is there an Apple or Fitbit smart or fitness watch that can monitor blood sugar?
The Answer to that is, by themselves no, however they will be able to show you the levels of your blood glucose during the day, alert you when needed and more with the help of a paired device.
In fact, the Dexcom G5 and the newest G6 Mobile App is compatible with Apple Watch. Pairing them, users can make use of it to see their glucose reading, trend graph as well as trend arrow discreetly.
For scrolling the trend graph view amid the data of one, three, or six hours, you can use the digital crown.
With a gadget like Apple watch, everyone is looking for a comprehensive device that cuts the need of getting a different one for a different purpose.
With the Dexcom sensor and app, your Apple Watch is now more than sufficient for keeping you informed about your blood glucose levels, making it one of the best wearable glucose monitors.
Dexcom app has recently started working flawlessly with Fitbit in the Ionic, Versa, and Versa light smartwatches as well. Thanks to the Dexcom CGM, the glucose data is read right from the wrist of the user.
This is what helps a great deal in merging the features of tracking of activities along with taking regular glucose readings that translates into better management of diabetes.
Fitbit has certainly been a leading name in the world of fitness trackers. With the Dexcom sensor and app, you can now use your favorite fitness tracker for Diabetes management as well.
2. Eversense Continuous Glucose Monitoring System– Accurate blood glucose stats on your phone
The Eversense Continuous Glucose Monitoring System is manufactured for accuracy that lasts for longer. Over and above that, it’s easy to use and is more beneficial in comparison to traditional CGM.
More interestingly, it alerts you in three different ways i.e., visually, auditory, as well as on-body vibe alerts. Thus, offering you an extra advantage of safety even when you are sleeping.
The developer of this CGM system is Senseonics Inc. and it comprises of a fluorescence-based sensor which is implantable, a mobile app and a smart transmitter.
Every 5 minutes, you get real-time monitoring of glucose with this CGM system and that too for more than three months at a time.
What’s more? The patient can see the trends and alerts as well as glucose values on its display via a compatible mobile device.
3. Guardian Connect System– easy-to-use blood Glucose monitor, works great with Apple watch
Medtronic MiniMed, Inc. is the developer of this current-era continuous glucose monitoring system. Every 5 minutes, it measures the levels of glucose.
On a compatible mobile device, the installation of the Guardian Connect app allows the patients to see their glucose values on the display.
This app displays sensor glucose data, alerts as well as trends in a user-friendly design. Furthermore, this app is a CGM system’s part and does not support insulin.
The system also comes with a tiny sensor that the user can wear for seven days. In addition to this, a discreet, slim Bluetooth® transmitter is also there which the user can wear almost at any place.
For one year of use or more, it only requires one rechargeable transmitter — contrary to other CGM systems whose transmitters require replacement four times as often.
The Guardian Connect System enables users of detecting trends as well as tracking patterns in glucose concentrations. By doing so, it aids in keeping with safe levels of blood glucose.
Users of Apple devices can also take advantage of this system for efficient monitoring of their blood glucose levels.
4. MiniMed 670G System– An advanced blood sugar monitor system
The developer of this MiniMed 670G System is again Medtronic MiniMed, Inc.
What makes this CGM system so special is that it’s the first hybrid closed-loop system approved by the FDA.
The hybrid closed-loop system possibly frees the individual from some of the everyday chores required for the stability of the blood glucose levels.
Or it might help the user in sleeping through nighttime by cutting the need for waking and testing glucose or taking medicine.
Nonetheless, consult your health care provider to know if this system is appropriate for you or not.
Noticeably, this CGM system is capable of monitoring glucose and adjusting the delivery of basal or long-acting insulin automatically on the basis of glucose reading of the user.
Besides, it comprises a continuous glucose monitor (CGM) for measurement of the glucose levels of the user for more than 7 days. Additionally, an insulin pump is also there delivering insulin to the user as well as a glucose meter for the calibration of the CGM.
More interestingly, this CGM system is capable of decreasing or stopping the delivery of insulin after detecting a fall in glucose levels of the user. Or rise in the glucose levels without his/her input.
5. Freestyle Libre
The system which was developed by Abbott has two parts – an electronic controller (the “reader”) and a one-time sensor suitable for 14 days of use. The sensor is small and circular in size of a coin, pinned to the back of the arm and measures the sugar level in the intercellular fluid using a tiny 5 mm long fiber.
The system is based on FLASH – Flash Glucose Monitoring technology, with a sensor located on the arm allowing scanning with an e-reader, showing the current sugar level, plus a trend arrow (detecting expected or decreasing sugar levels) and information on sugar levels in the past 8 hours.
The system is suitable for all diabetics and represents a real revolution in their quality of life, and in dealing with the management and balance of the disease.
To see the sugar level, the patient has to perform a “scan” operation – moving the controller over the sensor in less than a second, then the latest sugar level will appear on the controller monitor.
This process can be performed even when the sensor is under the clothing and up to 4 cm from the sensor. Sensor-to-reader communication is carried out using a standard wireless protocol, similar to what exists today on smartphones.
SugarBeat is hoping to change the CGM game with a device that uses a stick-on patch, not an under-the-skin sensor. The adhesive patch, about the size of a coin, sticks to skin and reports glucose levels (the company is tight-lipped on how, exactly, the device collects glucose data through the skin) every five minutes for 24 hours. A new patch is applied daily. A connected, rechargeable Bluetooth transmitter sends readings to a receiver or smartphone app. The device must be calibrated once daily with a finger stick. A European launch is planned for this year. The company plans to submit the device for FDA approval later this year.
Insulin in a pill? For years it seemed like a pipe dream, but at the end of 2017, Israeli company Oramed was gearing up for its phase 3 U.S. trial to deliver insulin via a pill. The concept was tricky: Stomach acids destroy the protein before it reaches the blood. But Oramed’s pill is absorbable from the intestine and is thought to act primarily on the liver, which regulates the insulin’s release. Under the conditions studied in the drug’s phase 2B trials, users saw effective blood glucose management without hypoglycemia. Once the phase 3 trial is complete, the company can submit the drug for FDA approval.
New and Improved
Further streamlining its tubeless, waterproof pump system, Insulet is developing the Omnipod Dash. The new system will see an update to the personal diabetes manager (PDM), the handheld device that connects with the pod to set basal and bolus rates. The current PDM is made by Insulet, but the Omnipod Dash’s PDM will be an Android smartphone—locked so it retains only pump functions, not apps or the ability to make calls—that will control insulin delivery and communicate via Bluetooth with the Contour Next blood glucose meter. Bluetooth is a big update for the Omnipod Dash system and will, Insulet hopes, open the door for cloud storage and communication between the pod and other devices, including continuous glucose monitors, in-the-works user and caregiver apps, and the ultimate goal: users’ personal smartphones. Because the Omnipod Dash is an improvement on an already existing device, Insulet isn’t required to conduct additional clinical trials before submitting to the FDA. The Omnipod Dash system should be available in limited U.S. markets this year, pending FDA approval this spring, with full availability three to six months after that. Insulet hopes to have a program allowing the pod to communicate with Dexcom CGMs in 2020.
2 comments - What do you think? Posted by
03/13/2019 at 11:26 am
Wearable glucose monitors will be made available to tens of thousands more people with type 1 diabetes from April 2019, NHS England has announced.
Its decision comes after an investigation found patients in some areas of the country were being denied access to the device.
It reduces the need for finger-prick blood tests and helps people with diabetes to manage their condition.
Diabetes charities called the change of policy a huge step forward.
In England, around 300,000 people have type 1 diabetes.
Under the current system, it is up to the individual clinical commissioning groups (CCGs) to decide whether flash glucose monitoring is available to patients in their area, which means the CCG can dictate the criteria for patients who are eligible for the device, and decide whether they offer it at all.
The device will be funded for people with Type 1 diabetes from 1 April 2019, from next year’s funding growth for local health groups which will allow access to flash monitoring throughout the country.
It is estimated that around 3-5% of patients with Type 1 diabetes in England have access to Freestyle Libre but if clinical commissioning groups (CCGs) were following the guidance correctly, this figure could eventually rise to at least 20-25%. Currently, 144 of 195 clinical commissioning groups have signed up, and today’s announcement mean thousands of patients still missing out will now get access.
4 comments - What do you think? Posted by
11/15/2018 at 10:06 am
Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch
LOUGHBOROUGH, England–Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month, also manufactured in the UK, in preparation for the anticipated sugarBEAT® product launch in the coming months.
SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals, and is expected to launch initially in the United Kingdom, upon CE Mark approval.
Dr Faz Chowdhury, CEO and chair of Nemaura Medical commented ‘We expect this initial order will support the successful launch of sugarBEAT® in the UK later this year, and also develop the capacities needed for subsequent scale up and launch in other countries which accept the CE Mark.’
Nemaura Medical recently completed a sugarBEAT® European three-stage clinical trial program consisting of 75 patients over 525 patient days in total, and have used this data to support their CE Mark application. A predecessor sugarBEAT® device, based on a wired wrist-watch form factor, received CE Mark approval in 2016.
About Nemaura Medical, Inc.
Nemaura Medical Inc. (NASDAQ: NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes.
SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals.
Diabetics may soon be able to pass on the traditional finger prick blood test to monitor their glucose levels.
A team from the University of Bath has developed a non-invasive adhesive patch that draws glucose out from fluid between cells across hair follicles that are individually accessed through an array of miniature sensors using a small electric current.
“A non-invasive—that is, needle-less—method to monitor blood sugar has proven a difficult goal to attain,” Richard Guy, a professor from the Department of Pharmacy & Pharmacology, said in a statement. “The closest that has been achieved has required either at least a single-point calibration with a classic ‘finger-stick,’ or the implantation of a pre-calibrated sensor via a single needle insertion. The monitor developed at Bath promises a truly calibration-free approach, an essential contribution in the fight to combat the ever-increasing global incidence of diabetes.”
With the patch, glucose is collected in small reservoirs. Measurements can be taken every 10 to 15 minutes over the course of several hours.
The test is advantageous to other wearable sensors because it can operate on a small area over an individual hair follicle—significantly reducing the inter-skin and intra-skin variability in glucose extraction and increasing the accuracy of the measurements taken so that calibration through a blood sample is not necessary.
“The specific architecture of our array permits calibration-free operation, and it has the further benefit of allowing realization with a variety of materials in combination,” Adelina Ilie, PhD, from the Department of Physics, said in a statement. “We utilized graphene as one of the components as it brings important advantages: specifically, it is strong, conductive, flexible, and potentially low-cost and environmentally friendly.
“In addition, our design can be implemented using high-throughput fabrication techniques like screen printing, which we hope will ultimately support a disposable, widely affordable device.”